In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea.
The in vitro activities of CG400549, a novel FabI inhibitor, were compared to those of linezolid and commonly used antimicrobials against recent bacterial isolates. CG400549 had an MIC(90) of 0.5 microg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin.
Yum
Jong Hwa
JH
Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea.
Kim
Chang Ki
CK
Yong
Dongeun
D
Lee
Kyungwon
K
Chong
Yunsop
Y
Kim
Cheol Min
CM
Kim
Jeong Mi
JM
Ro
Seonggu
S
Cho
Joong Myung
JM
D000081:Acetamides / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology; D050753:Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) / Q000037:antagonists & inhibitors* / Q000737:chemistry; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D007723:Korea / Q000453:epidemiology; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D023303:Oxazolidinones / Q000494:pharmacology; D011725:Pyridines / Q000009:adverse effects / Q000494:pharmacology; D013210:Staphylococcus / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics / Q000254:growth & development / Q000302:isolation & purification*; D013211:Staphylococcus aureus / Q000187:drug effects*; D058924:Thienopyridines; D013876:Thiophenes / Q000009:adverse effects / Q000494:pharmacology
D000081:Acetamides; D000890:Anti-Infective Agents; C523750:CG 400549; D004791:Enzyme Inhibitors; D023303:Oxazolidinones; D011725:Pyridines; D058924:Thienopyridines; D013876:Thiophenes; D050753:Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); D000069349:Linezolid